Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our recent studies have suggested that bacterial
lipopolysaccharide
(
LPS
) attaches to Pronase-sensitive proteins on the murine erythrocyte membrane. In the present study, in order to identify the
LPS-binding protein
on the murine erythrocyte membrane, a unique method to detect
LPS-binding protein
on a nitrocellulose membrane was developed. Murine erythrocyte membrane proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then transferred electrophoretically onto a nitrocellulose membrane. The membrane was incubated with
LPS
of Salmonella minnesota R595 (Re
LPS
) in phosphate-buffered saline (PBS), after the remaining sites were blocked with gelatin in PBS. We were able to obtain a non-background stain by adding the nonionic detergent octylglucoside at the low concentration of 0.1% to the Re
LPS
solution. The Re
LPS
bound to the protein on the nitrocellulose membrane was exposed to affinity purified anti-Re
LPS
antibodies (IgG) and then to alkaline phosphatase-conjugated anti-IgG. The alkaline phosphatase was detected on the membrane by an enzymatic reaction. This method demonstrated that Re
LPS
was bound to an erythrocyte protein of 96 kDa. Treatment of erythrocytes with Pronase led to disappearance of the Re
LPS-binding protein
on the erythrocyte membrane. There was no difference between
LPS
-responder and
LPS
-nonresponder murine erythrocyte membranes in amount and molecular weight of the Re
LPS-binding protein
.
...
PMID:Identification of Re lipopolysaccharide-binding protein on murine erythrocyte membrane. 245 83
Endotoxic
lipopolysaccharide
(
LPS
), a common structural component of all gram-negative bacteria, is well recognized for its capacity to interact with and perturb immunologically relevant cells. Using a radioiodinated, photoactivatable
LPS
probe, we have recently identified an 80-kilodalton
LPS
-specific binding protein on murine B lymphocytes. We now have extended these studies to determine if other mammalian species, as well as representative endotoxin-resistant species (frog and chicken), have a similar
LPS-binding protein
. We have identified what appears to be a relatively conserved 80-kilodalton
LPS-binding protein
on mononuclear cells of all mammalian species tested. However, both frog and chicken leukocytes failed to show the presence of a similar
LPS-binding protein
. It is possible that the presence of specific
LPS
-binding proteins may be important for endotoxin sensitivity of most mammalian species.
...
PMID:Endotoxic-lipopolysaccharide-specific binding proteins on lymphoid cells of various animal species: association with endotoxin susceptibility. 278 15
When incubated with
lipopolysaccharide
(
LPS
) in the presence of plasma, neutrophils become primed for enhanced release of superoxide in response to triggering by formyl-Met-Leu-Phe (fMLP). The effect of
LPS
on phagocytes is inhibited by a synthetic lipid A precursor, LA-14-PP (lipid IVa) or by
LPS
from Rhodobacter sphaeroides (Rs). We studied the mechanisms by which LA-14-PP or Rs-
LPS
inhibited
LPS
-induced responses. When neutrophils were exposed to LA-14-PP or Rs-
LPS
for 3 min and then to Escherichia coli-
LPS
, the antagonists inhibited priming for superoxide release, and also blocked up-regulation of CD11b and adherence. This inhibition was dependent on plasma, was not overcome by higher amounts of E. coli-
LPS
or plasma, and was not observed at 0 degrees C, suggesting that E. coli-
LPS
was not able to interact with its receptor or other cellular recognition molecule in neutrophils that had been exposed to the antagonists. The alternative possibility that LA-14-PP or Rs-
LPS
depleted a plasma cofactor, resulting in inhibition of priming, was investigated by using
LPS
from Porphyromonas gingivalis (Pg) and Bordetella pertussis (Bp). These
LPS
primed neutrophils in a plasma-dependent and CD14-dependent manner, but were not blocked by LA-14-PP or Rs-
LPS
. When sub-optimal concentrations of plasma were exposed to LA-14-PP or Rs-
LPS
, and then mixed with Pg-
LPS
or Bp-
LPS
, followed by incubation with neutrophils, priming and up-regulation of CD11b were inhibited, and this inhibition was overcome by increasing the concentration of plasma. Binding of
LPS-binding protein
(
LBP
) in plasma to immobilized E. coli-
LPS
was inhibited by pre-incubation of plasma with LA-14-PP or Rs-
LPS
. Together with the result that treatment of plasma with anti-
LBP
antibody abolished the cofactor activity of plasma, these results indicated that LA-14-PP and Rs-
LPS
depleted
LBP
from plasma, resulting in inability of
LPS
to act on neutrophils. Thus LA-14-PP and Rs-
LPS
inhibited the action of
LPS
on neutrophils by at least two mechanisms, blocking of
LPS
receptor recognition and depletion of the cofactor
LBP
.
...
PMID:An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. 749 65
Vascular endothelium activated by endotoxin (
lipopolysaccharide
[LPS]) and cytokines plays an important role in organ inflammation and blood leukocyte recruitment observed during sepsis. Endothelial cells can be activated by LPS directly, after its interaction with
LPS-binding protein
and soluble CD14 in plasma. LPS-
LPS-binding protein
complexes in blood also interact with monocytes and neutrophils bearing glycosyl-phosphatidylinositol (GPI) anchored membrane CD14 (mCD14), promoting the release of cytokines such as tumor necrosis factor and interleukin 1 (IL-1). These molecules, in turn, have the capacity to activate endothelial cells providing an indirect pathway for LPS-dependent endothelial cell activation. In this work, we address the relative importance of the direct and the indirect pathway of in vitro LPS-induced human umbilical vein endothelial cell (HUVEC) activation. Substituting whole blood for plasma resulted in a 1,000-fold enhancement of HUVEC sensitivity to LPS. Both blood- and plasma-dependent enhanced activation of HUVEC were blocked with an anti-CD14 monoclonal antibody. Blood from patients with paroxysmal nocturnal hemoglobinuria, whose cells lack mCD14 and other GPI anchored proteins, was unable to enhance LPS activation of HUVEC above the level observed with plasma alone. IL-10, an inhibitor of monocyte release of cytokines, decreased the blood-dependent enhancement of HUVEC activation by LPS. Blood adapted to small doses of LPS was also less efficient than nonadapted blood in producing this enhancement. Addition of purified mononuclear cells to HUVEC or the transfer of plasma from whole blood incubated with LPS to HUVEC, duplicated the enhancement effect observed when whole blood was incubated with HUVEC. Taken together, these data suggest that the indirect pathway of LPS activation of endothelial cell is mediated by monocytes and mCD14 through the secretion of a soluble mediator(s). The indirect pathway is far more efficient than the direct, plasma-dependent pathway.
...
PMID:A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. 750 60
CD14 is a 55-kD protein found as a glycosylphosphatidylinositol (GPI)-anchored protein on the surface of monocytes, macrophages, and polymorphonuclear leukocytes, and as a soluble protein in the blood. Both forms of CD14 participate in the serum-dependent responses of cells to bacterial
lipopolysaccharide
(
LPS
). While CD14 has been described as a receptor for complexes of
LPS
with
LPS-binding protein
(
LBP
), there has been no direct evidence showing whether a ternary complex of
LPS
,
LBP
, and CD14 is formed, or whether CD14 binds
LPS
directly. Using nondenaturing polyacrylamide gel electrophoresis (native PAGE), we show that recombinant soluble CD14 (rsCD14) binds
LPS
in the absence of
LBP
or other proteins. Binding of
LPS
to CD14 is stable and of low stoichiometry (one or two molecules of
LPS
per rsCD14). Recombinant
LBP
(rLBP) does not form detectable ternary complexes with rsCD14 and
LPS
, but it does accelerate the binding of
LPS
to rsCD14. rLBP facilitates the interaction of
LPS
with rsCD14 at substoichiometric concentrations, suggesting that
LBP
functions catalytically, as a lipid transfer protein. Complexes of
LPS
and rsCD14 formed in the absence of
LBP
or other serum proteins strongly stimulate integrin function on PMN and expression of E-selectin on endothelial cells, demonstrating that
LBP
is not necessary for CD14-dependent stimulation of cells. These results suggest that CD14 acts as a soluble and cell surface receptor for
LPS
, and that
LBP
may function primarily to accelerate the binding of
LPS
to CD14.
...
PMID:Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. 750
Several proteins modify the biological response to
lipopolysaccharide
(
LPS
). Both bactericidal/permeability-increasing factor (BPI), a protein stored in neutrophils, and the acute phase protein
LPS-binding protein
(
LBP
) bind to
LPS
; however, BPI inhibits while
LBP
enhances binding of
LPS
to leukocytes and subsequent induction of cytokines. We investigated plasma levels of BPI,
LBP
, elastase and C5a before, during and after hemodialysis (HD). Six patients were dialysed with Cuprophane (Cup) and polysulfone (PS) low-flux dialyzers on two consecutive HD sessions. There was a significant, 10.9 +/- 2.8-fold increase in BPI after 4-hour HD compared to predialysis and a 4.4 +/- 1.6-fold increase in elastase after 4-hour HD using Cup. Plasma levels of BPI and elastase decreased rapidly after the dialysis session. HD with PS resulted in a smaller, but still significant rise in BPI (3.7 +/- 1.6-fold at 4 hours) and elastase (1.69 +/- 0.2-fold at 4 hours). Levels for BPI and elastase were similar in the arterial and venous blood lines of the dialyzer. Plasma levels of
LBP
did not change during or after the HD session. These data indicate that BPI, but not
LBP
is released during HD with Cup and to a lesser extent with PS. Activation of neutrophils and release of BPI during HD may influence the biological response to bacterial products possibly introduced during HD.
...
PMID:Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis. 750 6
The signal transduction events that follow the binding of
lipopolysaccharide
(
LPS
) to the macrophage cell surface are not well defined. In the current studies
LPS
was found to induce alterations in phosphorylation of monocyte proteins on tyrosine. Herbimycin A and genistein, inhibitors of tyrosine kinases, markedly attenuated
LPS
-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) protein and mRNA production. Reciprocally, the tyrosine phosphatase inhibitor sodium orthovanadate enhanced
LPS
-induced production of TNF-alpha.
LPS
induced a concentration-dependent increase in tyrosine phosphorylation of several proteins, which paralleled and preceded the onset of
LPS
-induced TNF-alpha production.
LPS
stimulation had different but reproducible effects on three members of the src family of tyrosine kinases. Both Hck and Lyn kinase activity increased before the onset of TNF-alpha production, consistent with their participation in the observed
LPS
-induced tyrosine phosphoprotein accumulation. In contrast, Yes kinase activity was not affected. These observations were made at concentrations of
LPS
that required serum rich in
LPS-binding protein
and the monocyte surface antigen CD14 for TNF-alpha production. These data indicate that tyrosine kinases and phosphatases are involved in the signal transduction cascade by which
LPS
induces production of TNF-alpha and IL-6 by human monocytes, and suggest that Lyn and Hck are candidate participants in this process.
...
PMID:Lipopolysaccharide-induced cytokine production in human monocytes: role of tyrosine phosphorylation in transmembrane signal transduction. 751 9
Recent work has established the importance of serum proteins which interact with endotoxin (
lipopolysaccharide
, LPS) from Gram-negative bacteria. Thus human monocytes are activated after binding LPS complexed with a serum protein.
LPS-binding protein
(
LBP
) is a protein present in both normal and acute phase sera which binds LPS with high affinity. We describe the purification of
LBP
from human acute phase serum. The purification procedures combine preparative isoelectric focusing (IEF) and either preparative polyacrylamide gel electrophoresis (PAGE) or alternatively an anion-exchange chromatographic step using a Mono Q HR 5/5 column. This allows the isolation of biologically active
LBP
.
LBP
was characterized by N-terminal sequence analysis and by measuring the biological activity using flow cytometry (fluorescence-activated cell sorter, FACS) and a luminol enhanced chemiluminescence (LECL) assay.
...
PMID:Improved method for preparation of lipopolysaccharide-binding protein from human serum by electrophoretic and chromatographic separation techniques. 751 48
Endotoxic shock is associated with a coagulopathy, organ failure, and death. Tissue factor (TF) expression by monocytes exposed to bacterial endotoxin (
lipopolysaccharide
[LPS]) may mediate the coagulopathy and contribute to the high mortality of this disease. We examined the role of the
LPS-binding protein
(
LBP
)/CD14 receptor pathway in the LPS induction of TF expression in human monocytic THP-1 cells and peripheral blood monocytes. In THP-1 cells, the threshold concentration of LPS required to induce TF activity in serum-free medium was reduced 20-fold by purified
LBP
, which also enhanced TF mRNA synthesis. Similarly, monocytes cultured in the presence of serum were induced to express TF antigen at LPS concentrations 100 times lower than monocytes cultured in serum-free medium. An anti-
LBP
monoclonal antibody indicated that this effect was dependent on the presence of
LBP
in serum. LPS/
LBP
induction of TF activity and TF antigen expression in these monocytic cells were also inhibited by an anti-CD14 monoclonal antibody, indicating a requirement for the CD14 receptor. Thus, we suggest that low levels of LPS (5 to 100 pg/mL) present during sepsis induce TF expression in monocytes via the
LBP
/CD14-dependent pathway.
...
PMID:Role of the lipopolysaccharide (LPS)-binding protein/CD14 pathway in LPS induction of tissue factor expression in monocytic cells. 751 85
We have previously shown that human bactericidal/permeability-increasing protein (BPI) is able to inhibit serum-dependent
lipopolysaccharide
(
LPS
)-mediated activation of human monocytes and neutrophils in vitro, and to counteract the lethal effects of
LPS
challenge in vivo.
Lipopolysaccharide-binding protein
(
LBP
) is a serum protein which participates in
LPS
-mediated activation of cells (Tobias, P. S., Mathison, J., Mintz, D., Lee, J. D., Kravchenko, V., Kato, K., Pugin, J., and Ulevitch, R. J. (1992) Am. J. Respir. Cell. Mol. Biol. 7, 239-245). We have proposed that BPI functions in a negative feedback loop which opposes this activation (Marra, M. N., Wilde, C. G., Collins, M. S., Snable, J. L., Thornton, M. B., and Scott, R. W. (1992) J. Immunol. 148, 532-537). We have now cloned and expressed recombinant forms of human BPI and
LBP
. Here we demonstrate that purified recombinant human
LBP
can replace the serum requirement for both
LPS
binding to human monocytes and
LPS
-mediated secretion of tumor necrosis factor alpha from these cells. These activities of
LBP
are inhibited by a neutralizing anti-CD14 monoclonal antibody. We further demonstrate that purified recombinant human BPI can inhibit
LBP
-mediated
LPS
binding to cells and their subsequent activation. Comparison of the
LPS
binding properties of BPI and
LBP
in enzyme-linked immunosorbent type assays and in the Limulus amebocyte lysate assay suggest that BPI has a stronger affinity for
LPS
than does
LBP
. Direct competition between BPI and
LBP
for
LPS
may explain the inhibition by BPI of the proinflammatory effects of
LBP
in the presence of
LPS
.
...
PMID:Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation. 751 98
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>